Friday, February 03, 2017 7:11:24 AM
Fri February 3, 2017 7:00 AM|PR Newswire|About: SYN
ROCKVILLE, Md., Feb. 3, 2017 /PRNewswire/ -- Synthetic Biologics (SYN), Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics to preserve the microbiome to protect and restore the health of patients, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 13, 2017, at 4:00 p.m. (ET) at the Waldorf Astoria (Conrad room) in New York.
http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-2017-bio-ceo--investor-conference-300401771.html
============================
William Blair Bullish on Synthetic Biologics Inc (SYN) on Back of FDA Phase IIb/III Trial Design Approval
https://www.smarteranalyst.com/2017/01/20/william-blair-bullish-synthetic-biologics-inc-syn-following-fda-phase-iibiii-trial-design-approval/
"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.
Recent TOVX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:10:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:07:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:01:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:00:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:15:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 11:10:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 10:05:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 10:06:35 AM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 08/16/2023 09:24:26 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/15/2023 01:53:41 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/14/2023 09:11:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 08:30:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 01:03:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 12:10:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2023 01:22:02 PM
- Another Biotech Stealing The Premarket Spotlight • AllPennyStocks.com • 06/28/2023 02:15:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM